Dianthus (DNTH) director Jonathan Violin receives grant of 6,090 stock options

Rhea-AI Filing Summary

Dianthus Therapeutics director Jonathan Violin received a compensation-related stock option grant. He was awarded options to purchase 6,090 shares of common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.

The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that date. After this grant, he holds 6,090 stock options directly, with no open-market share purchases or sales reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Violin Jonathan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,090	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,090 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 6,090 options Exercise price: $89.63 per share Expiration date: May 21, 2036 +2 more

5 metrics

Options granted 6,090 options Stock option award to director on May 21, 2026

Exercise price $89.63 per share Strike price of stock option grant

Expiration date May 21, 2036 Option term end date

Underlying shares 6,090 shares Common stock underlying the options

Post-grant derivative holdings 6,090 options Total stock options held directly after this award

Key Terms

Stock Option (Right to Buy), exercise price, vest in full, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "89.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares of common stock underlying this stock option award will vest in full on the date"

Annual Meeting of Stockholders financial

"the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Violin Jonathan

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$89.63	05/21/2026		A		6,090		(1)	05/21/2036	Common Stock	6,090	$0	6,090	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Adam Veness, as attorney-in-fact for Jonathan Violin	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did DNTH director Jonathan Violin report in this Form 4 filing?

Jonathan Violin reported receiving a stock option grant for 6,090 shares of Dianthus Therapeutics common stock. The award is a compensation-related grant, not an open-market trade, and gives him the right to buy shares at a fixed exercise price.

How many DNTH stock options did Jonathan Violin receive and at what price?

He received options to buy 6,090 shares of Dianthus Therapeutics common stock at an exercise price of $89.63 per share. This price is the fixed cost he would pay per share if he exercises the options in the future.

When do Jonathan Violin’s DNTH stock options vest?

The options will vest in full on the earlier of the first anniversary of the grant date or Dianthus Therapeutics’ 2027 Annual Meeting of Stockholders. Vesting is conditioned on his continued service to the company through that date.

When do Jonathan Violin’s DNTH stock options expire?

The stock options expire on May 21, 2036. If they are not exercised by that expiration date, the right to purchase the 6,090 underlying shares at the $89.63 exercise price will lapse and become worthless.

Does this DNTH Form 4 show any insider buying or selling in the market?

No, the Form 4 shows only a grant of stock options as compensation to director Jonathan Violin. It does not report any open-market purchases or sales of Dianthus Therapeutics common stock by him in this filing.